Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure Tongue atrophy due to transthyretin-related familial amyloid polyneuropathy mimicking amyotrophic lateral sclerosis Tongue atrophy due to transthyretin-related.

Published byFrank Curtis Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure Tongue atrophy due to transthyretin-related familial amyloid polyneuropathy mimicking amyotrophic lateral sclerosis Tongue atrophy due to transthyretin-related."— Presentation transcript:

1 Figure Tongue atrophy due to transthyretin-related familial amyloid polyneuropathy mimicking amyotrophic lateral sclerosis Tongue atrophy due to transthyretin-related familial amyloid polyneuropathy mimicking amyotrophic lateral sclerosis (A) Marked tongue atrophy—note the furrowing of the lateral aspects of the tongue. Marked fasciculations were noted on examination along with muscle weakness (not shown). (B) A photomicrograph of a minor salivary gland biopsy showing an immunoperoxidase staining for transthyretin (TTR) (dark brown). Diffuse deposition of TTR-positive amyloid is seen in these glands. The patient did not meet inclusion criteria for the ongoing antisense oligonucleotide trial in familial amyloid polyneuropathy secondary to markedly abnormal neuropathy impairment score. Namita A. Goyal, and Tahseen Mozaffar Neurol Genet 2015;1:e18 © 2015 American Academy of Neurology

Download ppt "Figure Tongue atrophy due to transthyretin-related familial amyloid polyneuropathy mimicking amyotrophic lateral sclerosis Tongue atrophy due to transthyretin-related."

Similar presentations

A TWO YEAR OLD GIRL WITH PROGRESSIVE WEAKNESS Teaching NeuroImages Neurology Resident and Fellow Section © 2014 American Academy of Neurology.

A TWO YEAR OLD GIRL WITH PROGRESSIVE WEAKNESS Teaching NeuroImages Neurology Resident and Fellow Section © 2014 American Academy of Neurology.
A 68 year old woman with a troublesome chin tremor Teaching NeuroImages Neurology Resident and Fellow Section © 2013 American Academy of Neurology.

A 68 year old woman with a troublesome chin tremor Teaching NeuroImages Neurology Resident and Fellow Section © 2013 American Academy of Neurology.
Figure Pedigrees of the SCA42 families identified in this study

Figure Pedigrees of the SCA42 families identified in this study
Figure 2 ERG amplitude reduction in the follow-up study

Figure 2 ERG amplitude reduction in the follow-up study
Figure 2 ALSFRS-R changes (A) Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) slope after 6 months of treatment without (left)

Figure 2 ALSFRS-R changes (A) Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) slope after 6 months of treatment without (left)
Figure 1 Summary of prior diagnostic workup in neuromuscular disorder cases Summary of prior diagnostic workup in neuromuscular disorder cases Percentage.

Figure 1 Summary of prior diagnostic workup in neuromuscular disorder cases Summary of prior diagnostic workup in neuromuscular disorder cases Percentage.
Figure Family pedigree and clinical improvement with riboflavin treatment Family pedigree and clinical improvement with riboflavin treatment (A) The proband.

Figure Family pedigree and clinical improvement with riboflavin treatment Family pedigree and clinical improvement with riboflavin treatment (A) The proband.
M Waddington Cruz, A Berensztejn, MV Pinto, R Mundayat

M Waddington Cruz, A Berensztejn, MV Pinto, R Mundayat
Figure 2 Needle biopsy of the left vastus lateralis

Figure 2 Needle biopsy of the left vastus lateralis
Homozygosity for the V122I Mutation in Transthyretin Is Associated with Earlier Onset of Cardiac Amyloidosis in the African American Population in the.

Homozygosity for the V122I Mutation in Transthyretin Is Associated with Earlier Onset of Cardiac Amyloidosis in the African American Population in the.
Figure 2 Flow chart of patients who met the inclusion/exclusion criteria for the study Flow chart of patients who met the inclusion/exclusion criteria.

Figure 2 Flow chart of patients who met the inclusion/exclusion criteria for the study Flow chart of patients who met the inclusion/exclusion criteria.
Figure Vertebral artery angiogram and tissue pathology

Figure Vertebral artery angiogram and tissue pathology
Figure 2 Disease progression slowed during each round of Treg infusions and correlated with increased Treg suppressive function Disease progression slowed.

Figure 2 Disease progression slowed during each round of Treg infusions and correlated with increased Treg suppressive function Disease progression slowed.
Figure 3 Classical complement pathway activity and disease severity (A) Association between high innate classical pathway (CP) activity and degree of muscle.

Figure 3 Classical complement pathway activity and disease severity (A) Association between high innate classical pathway (CP) activity and degree of muscle.
Figure 2 Muscle pathology of patients 2, 26, 11, 9, 32, and 48

Figure 2 Muscle pathology of patients 2, 26, 11, 9, 32, and 48
Figure Muscle biopsy of the left biceps showing the characteristic pathologic findings in BCIM Muscle biopsy of the left biceps showing the characteristic.

Figure Muscle biopsy of the left biceps showing the characteristic pathologic findings in BCIM Muscle biopsy of the left biceps showing the characteristic.
Figure 3 Genetic pleiotropy in ALS

Figure 3 Genetic pleiotropy in ALS
Figure 2 FXTAS Rating Scale scores for case 1

Figure 2 FXTAS Rating Scale scores for case 1
Figure 2 Association between coronary artery disease polygenic risk score and the presence of migraine Results are given as odds ratios with 95% confidence.

Figure 2 Association between coronary artery disease polygenic risk score and the presence of migraine Results are given as odds ratios with 95% confidence.
Figure 2 Primary and secondary outcomes reported in multiple sclerosis (MS) disease-modifying therapy (DMT) clinical trials Primary and secondary outcomes.

Figure 2 Primary and secondary outcomes reported in multiple sclerosis (MS) disease-modifying therapy (DMT) clinical trials Primary and secondary outcomes.

Similar presentations

Ads by Google